Based on our Pharmacor Renal Cell Carcinoma advisory service, Decision Resources is offering an exclusive analyst call entitled Renal Cell Carcinoma: Will the Current Market Leader, Pfizer’s Sutent, be Challenged by the Changing Dynamics in this Crowded Market? Because this presentation features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.

Recorded live on Tuesday, July 13, 2010

This 15-minute analyst call, presented by Decision Resources Analyst Karen Pomeranz, M.Sc., Ph.D., answers the following questions:

• Over the next decade, how will the first-, second- and third-line treatment of advanced renal cell carcinoma evolve in the face of competing treatment options?
• Which agent will be the leading therapy in treatment of advanced (stage IV) renal cell carcinoma in 2019?
• What is the sales potential for the lead agent in each treatment line?

Contact us to learn how you can purchase this service and access a recorded playback of this event.

Click here to view the invite.